schliessen

Filtern

 

Bibliotheken

Insulin-like growth factor 1 and hearing impairment in older adults: results from the English Longitudinal Study of Ageing

Abstract Background Age-related hearing impairment is the most common hearing disorder, affecting two-thirds of people aged over 70 years in the UK. It is a major cause of disability, with considerable social and health implications, accompanied by a major economic burden. With the condition essenti... Full description

Journal Title: The Lancet (British edition) 2016, Vol.388, p.S65-S65
Main Author: Lassale, Camille, Dr
Other Authors: Batty, G David, DSc , Steptoe, Andrew, DSc , Zaninotto, Paola, PhD
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: London: Elsevier Ltd
ID: ISSN: 0140-6736
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_journals_1846738743
title: Insulin-like growth factor 1 and hearing impairment in older adults: results from the English Longitudinal Study of Ageing
format: Article
creator:
  • Lassale, Camille, Dr
  • Batty, G David, DSc
  • Steptoe, Andrew, DSc
  • Zaninotto, Paola, PhD
subjects:
  • Adults
  • Aged
  • Aging
  • Consortia
  • Correlation analysis
  • Decision analysis
  • Funding
  • Hearing loss
  • Insulin
  • Internal Medicine
  • Older people
ispartof: The Lancet (British edition), 2016, Vol.388, p.S65-S65
description: Abstract Background Age-related hearing impairment is the most common hearing disorder, affecting two-thirds of people aged over 70 years in the UK. It is a major cause of disability, with considerable social and health implications, accompanied by a major economic burden. With the condition essentially incurable, the focus becomes identification of risk factors. The biological determinants of hearing impairment remain poorly understood. Despite a suggestion from animal studies that insulin-like growth factor 1 (IGF-1) is implicated in the development of hearing impairment, we know of no studies in human beings. Methods 4398 participants with no missing data (mean age at baseline 64·2 years [SD 8·1], 55% women) from the English Longitudinal Study of Ageing provided serum concentrations of IGF-1 in 2008 and 2012. We used the average of these two measurement when available, one if not. Hearing acuity was measured with a HearCheck Screener (Siemens, Erlangen, Germany) in 2014. Hearing impairment was defined as hearing fewer than all six tones, three with decreasing intensity at two frequencies (1 kHz and 3 kHz). Logistic regression models were used to estimate odds ratios (OR) of hearing impairment across five quintiles of IGF-1 concentration. Presence of interaction and non-linearity were assessed by likelihood ratio tests. Findings Mean IGF-1 was 16·1 nmol/L (SD 5·2). In the full analytical sample, IGF-1 was not associated with subsequent hearing impairment (OR per 5 nmol increase in IGF-1 1·01, 95% CI 0·94–1·09). However, this association differed by age (pinteraction =0·03). Thus, in participants younger than 60 years (n=1402), IGF-1 was linearly associated with a lower risk of hearing impairment (0·85, 0·73–0·99) after adjustment for age, sex, smoking, height, body-mass index, cognitive function, education, and self-reported hearing at baseline. Among participants 60 years and older, there was some evidence of a J-shaped association (pcurvature =0·02). Compared with the lowest quintile of IGF-1, ORs for quintiles 2, 3, 4, and 5 were 0·94 (0·72–1·22), 1·13 (0·86–1·48), 0·97 (0·74–1·27), and 1·24 (0·95–1·62), respectively, but associations were not statistically significant. Interpretation In people at the lower end of the older-age spectrum, there was some support for lower levels of IGF-1 being linked with hearing impairment. These results warrant replication and then testing in trials of IGF-1 supplementation. Funding The English Longitudinal Study of A
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.4547658
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_journals_1846738743
sourceformatXML
sourcesystemPC
galeidA472808870
sourcerecordidA472808870
originalsourceidFETCH-LOGICAL-13693-39598c55452866f8e954834f214af82608236ac291f818ab6eaf4cad03b7ad8a3
addsrcrecordideNqFklFrFDEUhQdRcK3-BCXgi0KnJpNMJuuDspSqhQUfquBbyGZuZm87k2yTGcv6683uim2lIIHkJpzzcbk5RfGS0RNGmXx3QZmgpWy4fMPkW15xysrmUTFjohFlLZofj4vZX8nT4llKl5RSIWk9K36d-zT16Mser4B0MdyMa-KMHUMkjBjfkjWYiL4jOGwMxgH8SNCT0LcQiWmnfkzvSYS0K4iLYSDjGsiZ73pMa7IMvsNxatGbnlzkYkuCI4sOMvF58cSZPsGLP-dR8f3T2bfTL-Xy6-fz08WyZFzOecnn9VzZuhZ1paR0Cua1UFy4ignjVCWpqrg0tpozp5gyKwnGCWtayleNaZXhR8XrA3cTw_UEadSXYYq5oaSZEnkmqhH8VtWZHjR6F8Zo7IDJ6oVoKkWVamhWnTygyquFAW3w4DC_3zO8esCg7wqO7whWU0IPKW8Ju_WYOjOldJ9XH-Q2hpQiOL2JOJi41YzqXRr0Pg1699U63_Zp0E32fTz4IE_6J0LUySJ4Cy1GsKNuA_6X8OEfgs25QWv6K9hCup2pTpWmB8iOweSe0PDfc4HNdQ
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1846738743
display
typearticle
titleInsulin-like growth factor 1 and hearing impairment in older adults: results from the English Longitudinal Study of Ageing
sourceAlma/SFX Local Collection
creatorLassale, Camille, Dr ; Batty, G David, DSc ; Steptoe, Andrew, DSc ; Zaninotto, Paola, PhD
creatorcontribLassale, Camille, Dr ; Batty, G David, DSc ; Steptoe, Andrew, DSc ; Zaninotto, Paola, PhD
descriptionAbstract Background Age-related hearing impairment is the most common hearing disorder, affecting two-thirds of people aged over 70 years in the UK. It is a major cause of disability, with considerable social and health implications, accompanied by a major economic burden. With the condition essentially incurable, the focus becomes identification of risk factors. The biological determinants of hearing impairment remain poorly understood. Despite a suggestion from animal studies that insulin-like growth factor 1 (IGF-1) is implicated in the development of hearing impairment, we know of no studies in human beings. Methods 4398 participants with no missing data (mean age at baseline 64·2 years [SD 8·1], 55% women) from the English Longitudinal Study of Ageing provided serum concentrations of IGF-1 in 2008 and 2012. We used the average of these two measurement when available, one if not. Hearing acuity was measured with a HearCheck Screener (Siemens, Erlangen, Germany) in 2014. Hearing impairment was defined as hearing fewer than all six tones, three with decreasing intensity at two frequencies (1 kHz and 3 kHz). Logistic regression models were used to estimate odds ratios (OR) of hearing impairment across five quintiles of IGF-1 concentration. Presence of interaction and non-linearity were assessed by likelihood ratio tests. Findings Mean IGF-1 was 16·1 nmol/L (SD 5·2). In the full analytical sample, IGF-1 was not associated with subsequent hearing impairment (OR per 5 nmol increase in IGF-1 1·01, 95% CI 0·94–1·09). However, this association differed by age (pinteraction =0·03). Thus, in participants younger than 60 years (n=1402), IGF-1 was linearly associated with a lower risk of hearing impairment (0·85, 0·73–0·99) after adjustment for age, sex, smoking, height, body-mass index, cognitive function, education, and self-reported hearing at baseline. Among participants 60 years and older, there was some evidence of a J-shaped association (pcurvature =0·02). Compared with the lowest quintile of IGF-1, ORs for quintiles 2, 3, 4, and 5 were 0·94 (0·72–1·22), 1·13 (0·86–1·48), 0·97 (0·74–1·27), and 1·24 (0·95–1·62), respectively, but associations were not statistically significant. Interpretation In people at the lower end of the older-age spectrum, there was some support for lower levels of IGF-1 being linked with hearing impairment. These results warrant replication and then testing in trials of IGF-1 supplementation. Funding The English Longitudinal Study of Ageing is supported by the National Institute on Aging (grant numbers 2RO1AG7644 and 2RO1AG017644-01A1) and a consortium of the UK government departments coordinated by the Economic and Social Research Council. The funding bodies had no role in the study design; collection, analysis, and interpretation of data; writing of the abstract; and decision to submit the abstract for publication.
identifier
0ISSN: 0140-6736
1EISSN: 1474-547X
2DOI: 10.1016/S0140-6736(16)32301-7
languageeng
publisherLondon: Elsevier Ltd
subjectAdults ; Aged ; Aging ; Consortia ; Correlation analysis ; Decision analysis ; Funding ; Hearing loss ; Insulin ; Internal Medicine ; Older people
ispartofThe Lancet (British edition), 2016, Vol.388, p.S65-S65
rights
0Elsevier Ltd
12016 Elsevier Ltd
2COPYRIGHT 2016 Elsevier B.V.
3Copyright Elsevier Limited Nov 1, 2016
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
search
creatorcontrib
0Lassale, Camille, Dr
1Batty, G David, DSc
2Steptoe, Andrew, DSc
3Zaninotto, Paola, PhD
title
0Insulin-like growth factor 1 and hearing impairment in older adults: results from the English Longitudinal Study of Ageing
1The Lancet (British edition)
descriptionAbstract Background Age-related hearing impairment is the most common hearing disorder, affecting two-thirds of people aged over 70 years in the UK. It is a major cause of disability, with considerable social and health implications, accompanied by a major economic burden. With the condition essentially incurable, the focus becomes identification of risk factors. The biological determinants of hearing impairment remain poorly understood. Despite a suggestion from animal studies that insulin-like growth factor 1 (IGF-1) is implicated in the development of hearing impairment, we know of no studies in human beings. Methods 4398 participants with no missing data (mean age at baseline 64·2 years [SD 8·1], 55% women) from the English Longitudinal Study of Ageing provided serum concentrations of IGF-1 in 2008 and 2012. We used the average of these two measurement when available, one if not. Hearing acuity was measured with a HearCheck Screener (Siemens, Erlangen, Germany) in 2014. Hearing impairment was defined as hearing fewer than all six tones, three with decreasing intensity at two frequencies (1 kHz and 3 kHz). Logistic regression models were used to estimate odds ratios (OR) of hearing impairment across five quintiles of IGF-1 concentration. Presence of interaction and non-linearity were assessed by likelihood ratio tests. Findings Mean IGF-1 was 16·1 nmol/L (SD 5·2). In the full analytical sample, IGF-1 was not associated with subsequent hearing impairment (OR per 5 nmol increase in IGF-1 1·01, 95% CI 0·94–1·09). However, this association differed by age (pinteraction =0·03). Thus, in participants younger than 60 years (n=1402), IGF-1 was linearly associated with a lower risk of hearing impairment (0·85, 0·73–0·99) after adjustment for age, sex, smoking, height, body-mass index, cognitive function, education, and self-reported hearing at baseline. Among participants 60 years and older, there was some evidence of a J-shaped association (pcurvature =0·02). Compared with the lowest quintile of IGF-1, ORs for quintiles 2, 3, 4, and 5 were 0·94 (0·72–1·22), 1·13 (0·86–1·48), 0·97 (0·74–1·27), and 1·24 (0·95–1·62), respectively, but associations were not statistically significant. Interpretation In people at the lower end of the older-age spectrum, there was some support for lower levels of IGF-1 being linked with hearing impairment. These results warrant replication and then testing in trials of IGF-1 supplementation. Funding The English Longitudinal Study of Ageing is supported by the National Institute on Aging (grant numbers 2RO1AG7644 and 2RO1AG017644-01A1) and a consortium of the UK government departments coordinated by the Economic and Social Research Council. The funding bodies had no role in the study design; collection, analysis, and interpretation of data; writing of the abstract; and decision to submit the abstract for publication.
subject
0Adults
1Aged
2Aging
3Consortia
4Correlation analysis
5Decision analysis
6Funding
7Hearing loss
8Insulin
9Internal Medicine
10Older people
issn
00140-6736
11474-547X
fulltexttrue
rsrctypearticle
creationdate2016
recordtypearticle
recordideNqFklFrFDEUhQdRcK3-BCXgi0KnJpNMJuuDspSqhQUfquBbyGZuZm87k2yTGcv6683uim2lIIHkJpzzcbk5RfGS0RNGmXx3QZmgpWy4fMPkW15xysrmUTFjohFlLZofj4vZX8nT4llKl5RSIWk9K36d-zT16Mser4B0MdyMa-KMHUMkjBjfkjWYiL4jOGwMxgH8SNCT0LcQiWmnfkzvSYS0K4iLYSDjGsiZ73pMa7IMvsNxatGbnlzkYkuCI4sOMvF58cSZPsGLP-dR8f3T2bfTL-Xy6-fz08WyZFzOecnn9VzZuhZ1paR0Cua1UFy4ignjVCWpqrg0tpozp5gyKwnGCWtayleNaZXhR8XrA3cTw_UEadSXYYq5oaSZEnkmqhH8VtWZHjR6F8Zo7IDJ6oVoKkWVamhWnTygyquFAW3w4DC_3zO8esCg7wqO7whWU0IPKW8Ju_WYOjOldJ9XH-Q2hpQiOL2JOJi41YzqXRr0Pg1699U63_Zp0E32fTz4IE_6J0LUySJ4Cy1GsKNuA_6X8OEfgs25QWv6K9hCup2pTpWmB8iOweSe0PDfc4HNdQ
startdate2016
enddate2016
creator
0Lassale, Camille, Dr
1Batty, G David, DSc
2Steptoe, Andrew, DSc
3Zaninotto, Paola, PhD
general
0Elsevier Ltd
1Elsevier B.V
2Elsevier Limited
scope
0AAYXX
1CITATION
2BKMMT
3BSHEE
40TT
50TZ
60U~
73V.
87QL
97QP
107RV
117TK
127U7
137U9
147X7
157XB
1688A
1788C
1888E
1988G
2088I
218AF
228AO
238C1
248C2
258FE
268FH
278FI
288FJ
298FK
308G5
31ABUWG
32AN0
33ASE
34AZQEC
35BBNVY
36BEC
37BENPR
38BHPHI
39C1K
40DWQXO
41FPQ
42FYUFA
43GHDGH
44GNUQQ
45GUQSH
46H94
47HCIFZ
48K6X
49K9-
50K9.
51KB0
52KB~
53LK8
54M0R
55M0S
56M0T
57M1P
58M2M
59M2O
60M2P
61M7N
62M7P
63MBDVC
64NAPCQ
65PQEST
66PQQKQ
67PQUKI
68Q9U
69S0X
sort
creationdate2016
titleInsulin-like growth factor 1 and hearing impairment in older adults: results from the English Longitudinal Study of Ageing
authorLassale, Camille, Dr ; Batty, G David, DSc ; Steptoe, Andrew, DSc ; Zaninotto, Paola, PhD
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-13693-39598c55452866f8e954834f214af82608236ac291f818ab6eaf4cad03b7ad8a3
rsrctypearticles
prefilterarticles
languageeng
creationdate2016
topic
0Adults
1Aged
2Aging
3Consortia
4Correlation analysis
5Decision analysis
6Funding
7Hearing loss
8Insulin
9Internal Medicine
10Older people
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Lassale, Camille, Dr
1Batty, G David, DSc
2Steptoe, Andrew, DSc
3Zaninotto, Paola, PhD
collection
0CrossRef
1Gale General OneFile (A&I only)
2Academic OneFile (A&I only)
3News PRO
4Pharma and Biotech Premium PRO
5Global News & ABI/Inform Professional
6ProQuest Central (Corporate)
7Bacteriology Abstracts (Microbiology B)
8Calcium & Calcified Tissue Abstracts
9Nursing & Allied Health Database
10Neurosciences Abstracts
11Toxicology Abstracts
12Virology and AIDS Abstracts
13Health & Medical Collection
14ProQuest Central (purchase pre-March 2016)
15Biology Database (Alumni Edition)
16Healthcare Administration Database (Alumni)
17Medical Database (Alumni Edition)
18Psychology Database (Alumni)
19Science Database (Alumni Edition)
20STEM Database
21ProQuest Pharma Collection
22Public Health Database
23Lancet Titles
24ProQuest SciTech Collection
25ProQuest Natural Science Collection
26Hospital Premium Collection
27Hospital Premium Collection (Alumni Edition)
28ProQuest Central (Alumni) (purchase pre-March 2016)
29Research Library (Alumni Edition)
30ProQuest Central (Alumni Edition)
31British Nursing Database
32British Nursing Index
33ProQuest Central Essentials
34Biological Science Collection
35eLibrary
36ProQuest Central
37Natural Science Collection
38Environmental Sciences and Pollution Management
39ProQuest Central Korea
40British Nursing Index (BNI) (1985 to Present)
41Health Research Premium Collection
42Health Research Premium Collection (Alumni)
43ProQuest Central Student
44Research Library Prep
45AIDS and Cancer Research Abstracts
46SciTech Premium Collection
47British Nursing Index
48Consumer Health Database (Alumni Edition)
49ProQuest Health & Medical Complete (Alumni)
50Nursing & Allied Health Database (Alumni Edition)
51ProQuest Newsstand Professional
52ProQuest Biological Science Collection
53Consumer Health Database
54Health & Medical Collection (Alumni Edition)
55Healthcare Administration Database
56Medical Database
57Psychology Database
58Research Library
59Science Database
60Algology Mycology and Protozoology Abstracts (Microbiology C)
61Biological Science Database
62Research Library (Corporate)
63Nursing & Allied Health Premium
64ProQuest One Academic Eastern Edition
65ProQuest One Academic
66ProQuest One Academic UKI Edition
67ProQuest Central Basic
68SIRS Editorial
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Lassale, Camille, Dr
1Batty, G David, DSc
2Steptoe, Andrew, DSc
3Zaninotto, Paola, PhD
formatjournal
genrearticle
ristypeJOUR
atitleInsulin-like growth factor 1 and hearing impairment in older adults: results from the English Longitudinal Study of Ageing
jtitleThe Lancet (British edition)
date2016
risdate2016
volume388
spageS65
epageS65
pagesS65-S65
issn0140-6736
eissn1474-547X
abstractAbstract Background Age-related hearing impairment is the most common hearing disorder, affecting two-thirds of people aged over 70 years in the UK. It is a major cause of disability, with considerable social and health implications, accompanied by a major economic burden. With the condition essentially incurable, the focus becomes identification of risk factors. The biological determinants of hearing impairment remain poorly understood. Despite a suggestion from animal studies that insulin-like growth factor 1 (IGF-1) is implicated in the development of hearing impairment, we know of no studies in human beings. Methods 4398 participants with no missing data (mean age at baseline 64·2 years [SD 8·1], 55% women) from the English Longitudinal Study of Ageing provided serum concentrations of IGF-1 in 2008 and 2012. We used the average of these two measurement when available, one if not. Hearing acuity was measured with a HearCheck Screener (Siemens, Erlangen, Germany) in 2014. Hearing impairment was defined as hearing fewer than all six tones, three with decreasing intensity at two frequencies (1 kHz and 3 kHz). Logistic regression models were used to estimate odds ratios (OR) of hearing impairment across five quintiles of IGF-1 concentration. Presence of interaction and non-linearity were assessed by likelihood ratio tests. Findings Mean IGF-1 was 16·1 nmol/L (SD 5·2). In the full analytical sample, IGF-1 was not associated with subsequent hearing impairment (OR per 5 nmol increase in IGF-1 1·01, 95% CI 0·94–1·09). However, this association differed by age (pinteraction =0·03). Thus, in participants younger than 60 years (n=1402), IGF-1 was linearly associated with a lower risk of hearing impairment (0·85, 0·73–0·99) after adjustment for age, sex, smoking, height, body-mass index, cognitive function, education, and self-reported hearing at baseline. Among participants 60 years and older, there was some evidence of a J-shaped association (pcurvature =0·02). Compared with the lowest quintile of IGF-1, ORs for quintiles 2, 3, 4, and 5 were 0·94 (0·72–1·22), 1·13 (0·86–1·48), 0·97 (0·74–1·27), and 1·24 (0·95–1·62), respectively, but associations were not statistically significant. Interpretation In people at the lower end of the older-age spectrum, there was some support for lower levels of IGF-1 being linked with hearing impairment. These results warrant replication and then testing in trials of IGF-1 supplementation. Funding The English Longitudinal Study of Ageing is supported by the National Institute on Aging (grant numbers 2RO1AG7644 and 2RO1AG017644-01A1) and a consortium of the UK government departments coordinated by the Economic and Social Research Council. The funding bodies had no role in the study design; collection, analysis, and interpretation of data; writing of the abstract; and decision to submit the abstract for publication.
copLondon
pubElsevier Ltd
doi10.1016/S0140-6736(16)32301-7